Shareholder Alert: Ademi LLP investigates whether Icosavax, Inc. has obtained a Fair Price in its transaction with AstraZeneca


MILWAUKEE, Dec. 12, 2023 /PRNewswire/ — Ademi LLP is investigating Icosavax (Nasdaq: ICVX) for possible breaches of fiduciary duty and other violations of law in its transaction with AstraZeneca.

AdemiLogo (PRNewsfoto/Ademi LLP)

Click here to learn how to join the or call Guri Ademi toll-free at 866-264-3995.  There is no cost or obligation to you.

In the transaction, Icosavax stockholders are expected to receive only $15.00 per share in cash at closing, plus a non-tradable contingent value right to receive up to $5.00 in cash, payable upon achievement of specified regulatory and net sales milestones. The transaction agreement unreasonably limits competing transactions for Icosavax by imposing a significant penalty if Icosavax accepts a competing bid. Icosavax insiders will receive substantial benefits as part of change of control arrangements.

We are investigating the conduct of Icosavax’s board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.

If you own Icosavax common stock and wish to obtain additional information, please contact Guri Ademi either at [email protected] or toll-free: 866-264-3995, or                       

We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights throughout the country. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.


Ademi LLP                                                                    

Guri Ademi

Toll Free: (866) 264-3995

Fax: (414) 482-8001

Cision View original content to download multimedia:


Disclaimer: The above press release comes to you under an arrangement with PR Newswire. takes no editorial responsibility for the same.